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ABSTRACT
In moderate and strong cancer pain oxycodone has become one of the most effective and popular opioids. A com-
bination of prolonged-release oxycodone with prolonged-release naloxone is a valued option among patients 
suffering from pain and opioid–induced bowel dysfunction (OIBD).
We present a case of a male cancer patient with chronic constipation effectively treated with oxycodone/nalox-
one combination.
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Introduction
For the last few decades, the World Health Organisa-
tion’s (WHO) analgesic ladder has remained a basis for 
decisions made in order to palliate chronic pain. How-
ever, its basic form, which includes non-opioid drugs, 
weak and strong opioids, as well as coanalgesic drugs, 
is undergoing modifications and is being discussed. The 
role of drugs of the second ‘step’ of the ladder, treating 
neuropathic pain, transient pain management, or aiming 
at minimisation of adverse drug reactions, remains a sub-
ject of discussion [1, 2]. The latter issue has a particular 
importance in a situation when we reach (or we would 
be able to reach) a desired analgesic effect, but we are 
forced to stop the treatment when the adverse effects of 
the therapy exceed its observed advantages. In clinical 
practice we face such a situation in cases of occurrence 
and increase of opioid-induced bowel dysfunction 
(OIBD), among others. 
Case report
A 68-year-old man was admitted into the care of 
a home hospice in advanced stage of right thigh sarcoma 
with lung metastases. In the 1990s the patient underwent 
a bilateral nephrectomy at different times due to poly-
cystic kidney disease, with follow-up haemodialysis for 
many years. The patient was under the constant care of 
the nephrologist, he chronically used antihypertensive 
drugs, and for many years he complained of habitual 
constipations related to multiple hospitalisations, re-
striction of fluid intake, and decreased physical activity. 
Four years before diagnosis of the sarcoma, a successful 
kidney transplantation from the unrelated donor was 
conducted. The patient was on immunosuppressive 
drugs. Due to improvement in the patient’s general 
condition, including an increase in everyday physical 
activity and decrease in body weight, the doses of the 
antihypertensive drugs were reduced, and the patient 
only sporadically required laxatives.
In 2014, the sarcoma of the right thigh was diagnosed. 
Despite surgical therapy, radiotherapy, and chemothera-
py we observed rapid progression of the disease with the 
development of lung metastases and increased pain in 
the right lower limb. Due to bad tolerance to tramadolol 
(nausea, dizziness) and the nephrologist’s recommen-
dation to reduce the non-steroidal anti-inflammatory 
drugs to emergency doses, the primary care physician 
ordered administration of prolonged-release morphine 
in an initial dose of 20 mg per day. Due to incomplete 
pain control (NRS score: 6 at rest, 8 in movement) the 
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patient reduced his physical activity. At the same time 
a renewed increase in constipation incidences was ob-
served. The attending physician decided to discontinue 
morphine, and introduced fentanyl TTS in a dose gradu-
ally increasing to 75 μg/h every 3 days. Control of pain 
at rest was improved (NRS 4), while the intensity of 
symptoms during physical activity ranged between 7 and 
8 NRS score. The patient still complained of persistent 
feeling of fullness in the abdominal cavity and a sensa-
tion of incomplete defecation. Commonly used means 
(fibre, bran, senna) did not improve his condition. The 
tolerance of lactulose was bad (nausea), and due to its 
poor effects patient refused to take the drug. Difficul-
ties in defecation were connected to the necessity of 
long stays in the toilet, which enhanced the thigh pain. 
Due to the disease stage, the oncologist decided to 
refer the patient to the care of a home hospice. At ad-
mission, the patient’s general condition was moderate, 
with full logical contact. He was able to move around the 
apartment on his own, he also decided on his own about 
taking numerous drugs. The patient was supported by 
his wife in his everyday functioning. In her opinion, the 
pain control was insufficient. The patient’s wife thought 
that the patient dissimulated because he did not want to 
worry his family. On the other hand, she thought that 
her husband overestimated the problem with proper 
defecation (“Instead of reporting to the doctor the thigh 
pain, he constantly asks about the constipations, and 
yet he hardly eats”). Due to the above-mentioned pain 
intensity (NRS 4 at rest and 7 in movement) and a sen-
sation of significant discomfort in the abdominal cavity 
(flatulence, periodically painful distension) the hospice 
physician decided to include a preparation of oxycodone 
with naloxone in a total dose of 30 mg + 15 mg every 
12 hours. The fentanyl TTS was discontinued. Significant 
reduction of dyspeptic symptoms, remission of nausea, 
and an increase in the frequency of defecations to three 
times per week was obtained. However, the patient 
reported a lack of improvement of the pain relief and 
temporary intensification of the ailments. The dose was 
increased to 40 mg of oxycodone in combination with 
20 mg of naloxone every 12 hours. A decrease in the 
intensity of pain to 1–2 points at rest and 4 in movement 
and normalisation of the defecation rhythm was reached. 
In the case of the transient pain occurring 1–2 times 
a day (NRS 6–7) an oral solution of oxycodone was used. 
A dose of 15 mg was assessed as sufficient by the patient.
Continued progression of the disease was observed as 
well as the necessity of staying in bed due to his general 
condition, increasing exhaustion, and dependence on the 
carers, and also concerning the administration of drugs. 
In this period, a difficult to explain increase in pain 
was observed for several days, although the ailments 
were well controlled at rest. The answer was found 
after a conversation with the patient’s wife. Unsure 
about what drugs her husband had already taken (as 
mentioned earlier, the patient previously controlled 
them on his own), she significantly reduced the dose of 
the recommended oxycodone/naloxone because of the 
fact that constipations subsided (“Now I do not give him 
this thing for the constipations”). Thus, the indications 
and necessity of regular use of the analgesic in the dose 
recommended by the physician was explained to the 
patient’s wife one more time. The pain ailments were 
again significantly alleviated. The patient died due to the 
advanced stage of the neoplastic process with depletion. 
The 40/20 mg oxycodone/naloxone dose every 12 hours 
provided good pain control until the patient’s death.
Discussion
Relieving the pain ailments is one of the main aims of 
palliative care of terminally ill patients [2]. Establishing 
the causes, type, and intensity of pain and implementa-
tion of adequate procedure [3] remains the subject of 
attention. An increasingly broad role in chronic pain 
treatment is played by the application of drugs in the 
third step of the analgesic ladder, including oxycodone 
[4–6]. The drug, similarly to other strong opioids, is used 
in cases when there is no effect of applying the first- and 
second-step drugs, in cases of intolerance to drugs of the 
third step, and in cases of rotation of opioids [7]. Clinical 
research indicates the effectiveness of oxycodone in vis-
ceral and somatic pain and in treating neuropathic pain 
[8–10]. The results of the meta-analysis conducted by 
Wang et al. confirm the high effectiveness of oxycodone 
in controlling pain in comparison to codeine sulphate, 
tramadol, and other strong opioids [8]. 
However, therapeutic possibilities are often limited 
by the adverse drug reactions, including the opioid-in-
duced bowel dysfunction, occurring in patients treated 
for cancer pain as well as for pain not related to cancer 
[11]. Incidence of constipations is also influenced by fac-
tors that are not directly connected to opioids, among 
others (similarly to the presented patient), coexisting 
conditions, other taken drugs, decrease in fluid intake, 
overusing laxatives in the past, and others. The laxatives 
prescribed prophylactically and during the opioid therapy 
can improve bowel function. Nevertheless, a significant 
number of patients do not obtain reduction of OIBD 
symptoms due to their complex nature [11]. OIBD can 
occur in 65–85% of patients treated with opioids, despite 
the fact that the majority of patients (80–90%) takes 
laxatives [12, 13]. Due to the complex nature of OIBD 
and ‘environmental’ factors (no privacy, bad hygienic 
conditions, feeling of embarrassment, etc.) commonly 
used laxatives do not give (as in the described case) 
expected results [13]. In the studies by Papagallo et al., 
among patients suffering from cancer pain, constipation 
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(less than three full defecations per week) related to the 
taken opioids was diagnosed in about 40% of patients (in 
comparison to 7.6% in the control group). Among those 
who required laxatives, the expected effect of treating 
constipations was reached only in 46% of patients treated 
with opioids (84% in the control group) [11]. 
The basic symptoms of OIBD do not go away and 
can even increase with the course of taking opioids [4, 
14]. Constipations, forming dry, hard stools, flatulence, 
convulsive abdominal pain, heartburn, nausea, and vom-
iting are often the reasons for using too low drug doses 
or even resigning from the treatment [13, 15]. Those 
symptoms decrease patients’ comfort of life and their 
everyday activity, and lower the anti-pain effectiveness 
of analgesics [11–13]. Moreover, the convulsive abdomi-
nal pain from intolerance to anthracene compounds or 
nausea and flatulence with the usage of lactulose can 
additionally deteriorate the quality of life of patients.
It needs to be remembered that we can talk about 
the opioid-induced constipations when a patient using 
weak or strong opioid suffers from lowered frequency 
of defecations (below three per week) or when a patient 
reports difficulties with defecation, sensation of incom-
plete defecation, discharging stool with strong effort, or 
evacuating hard stool. The so-called Bowel Function 
Index (BFI) can also be helpful in the assessment of 
the problem [14, 16, 17]. The three basic parameters: 
difficulties in defecation, sensation of incomplete def-
ecation, and assessment of the constipation intensity 
occurring in the last 7 days are scored on a scale from 
0 to 100 (or 0 to 10). An average score of over 28.8 (over 
2.9, respectively) gives a diagnosis of constipation [14, 
18]. Assessment using the BFI allows confirmation of 
the effectiveness of the oxycodone/naloxone compound 
preparation in OIBD. It is worth noting the results of the 
research by Hermanns et al., in which implementation 
of pain treatment using oxycodone/naloxone resulted 
in reduction of the BFI score value from 41.6 ± 31.6 to 
16.5 ± 19.6 (p < 0.001) with an increase in the estimated 
quality of life by 47% at the same time [16].
Incidents of adverse drug reactions can be the reason 
for the decision to change one opioid to another (rota-
tion of opioids). In the mentioned work of Wang et al. 
better tolerance and much less frequent incidence of 
nausea and constipations was proven in patients treated 
with oxycodone in comparison to the remaining groups 
(p = 0.01) [8]. In the research of Rosti et al., concern-
ing factors predisposing patients under pain treatment 
to OIBD, an association between different opioids and 
different risk of the incidence of these symptoms was 
shown. Morphine was associated with the highest fre-
quency of constipation, and the lowest risk was noted 
for oxycodone and buprenorphine TTS. The OIBD 
incidence was significantly influenced by the coexistence 
of neoplastic disease, old age, and using fentanyl [12]. 
The search for proper procedures, based on mecha-
nisms of OIBD development, led to use of a combination 
of a strong opioid with an opioid receptor antagonist 
in treating patients with constipations for cancer pain 
[11]. Naloxone shows a much stronger affinity to opioid 
receptors in the intestinal wall than does oxycodone. Its 
peripheral action leads to the improvement of bowel 
function and reduction of the problem of constipation. 
Additionally, naloxone is almost entirely eliminated in 
the liver, while the active form of oxycodone is absorbed 
into the blood circulation and its central analgesic action 
is undisturbed. Clinical research confirms that naloxone 
does not lower the painkilling effectiveness of oxycodone 
in treating cancer pain as well as non-cancer pain [16, 17, 
19, 20]. The combination of oxycodone with naloxone 
remains an effective analgesic in this mechanism, simul-
taneously showing a significant beneficial influence on 
prophylaxis and treatment of OIBD [19–22]. The basic 
contraindications to use oxycodone/naloxone include 
hepatic dysfunction, nephrolithiasis, paralytic ileus, 
other obstructive and inflammatory intestine conditions, 
pancreatitis, diarrhoea, and hypersensitivity to the ingre-
dients of the preparation. Proper selection of the drug 
dose is necessary. In the presented case, the estimated 
initial dose proved not entirely effective (pehaps due to 
the insufficient analgesic effect of fentanyl TTS). Good 
control was achieved after implementation of the daily 
dose of 80 + 40 mg and 15–30 mg of oxycodone solution in 
cases of transient pain. In our patient’s opinion, he did not 
require a higher total dose of oxycodone, although there 
was such a possibility. It is noteworthy that the maximum 
daily dose of oxycodone/naloxone is 160/80 mg per day. 
Summary
The management of pain with the use of prepa-
rations combining oxycodone and opioid receptors’ 
antagonist ensures reduction of pain while preventing 
or decreasing OIBD symptoms at the same time. It 
improves not only the patient’s physical condition but 
also his/her psychological condition and contact with 
the surrounding environment allowing him/her to par-
ticipate in family life [8]. The compound preparation 
of oxycodone/naloxone, being an effective analgesic, 
reduces constipations and other dyspeptic symptoms, 
thus improving the quality of patients’ lives.
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